Literature DB >> 22491046

Antiemesis.

David S Ettinger1, Debra K Armstrong, Sally Barbour, Michael J Berger, Philip J Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D Kloth, Mark G Kris, Dean Lim, Laura Boehnke Michaud, Lida Nabati, Kim Noonan, Hope S Rugo, Darby Siler, Steven M Sorscher, Sundae Stelts, Lisa Stucky-Marshall, Barbara Todaro, Susan G Urba.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22491046     DOI： 10.6004/jnccn.2012.0047

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  26 in total

1.  Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

Authors:  Terry L Ng; Brian Hutton; Mark Clemons
Journal:  Oncologist       Date:  2015-05-06

Review 2.  Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.

Authors:  Naoki Inui
Journal:  Med Oncol       Date:  2017-04-01       Impact factor: 3.064

3.  Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.

Authors:  Hyo Jung Kim; Sang Won Shin; Eun-Kee Song; Na-Ri Lee; Jun Suk Kim; Jin Seok Ahn; Hwan-Jung Yun; Yo-Han Cho; Keon Uk Park; Si-Young Kim; Joung Soon Jang; Sang-We Kim; Hyun Woo Lee; Se Ryeon Lee; Yang Soo Kim; Soon Nam Lee; Yoon Ho Ko; Hwa Jung Kim; Jin-Hyoung Kang
Journal:  Oncologist       Date:  2015-10-28

4.  The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.

Authors:  Yinting Chen; Linjuan Zeng; Yong Wang; William H Tolleson; Bridgett Knox; Si Chen; Zhen Ren; Lei Guo; Nan Mei; Feng Qian; Kaihong Huang; David Liu; Weida Tong; Dianke Yu; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-08-16       Impact factor: 5.858

5.  Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.

Authors:  Seiichiro Suzuki; Masato Karayama; Naoki Inui; Shigeki Kuroishi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Koshi Yokomura; Mikio Toyoshima; Shiro Imokawa; Kazuhiro Asada; Masafumi Masuda; Takashi Yamada; Hiroshi Watanabe; Hiroshi Hayakawa; Takafumi Suda
Journal:  Med Oncol       Date:  2016-05-27       Impact factor: 3.064

Review 6.  Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.

Authors:  Hyun Jin Song; Hyun-Ju Seo; Heejeong Son
Journal:  Eur J Clin Pharmacol       Date:  2016-08-15       Impact factor: 2.953

7.  Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China.

Authors:  Xianglong Zong; Jie Zhang; Xin Ji; Jie Gao; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

Review 8.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

9.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

10.  Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.

Authors:  Hideaki Yahata; Hiroaki Kobayashi; Kenzo Sonoda; Mototsugu Shimokawa; Tatsuhiro Ohgami; Toshiaki Saito; Shinji Ogawa; Kunihiro Sakai; Akimasa Ichinoe; Yousuke Ueoka; Yasuyuki Hasuo; Makoto Nishida; Satohiro Masuda; Kiyoko Kato
Journal:  Int J Clin Oncol       Date:  2015-12-10       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.